Tempest Therapeutics, Inc. has announced that the U.S. FDA has granted a "Study May Proceed" letter for their Phase 2 clinical trial of TPST-1495, a novel dual receptor inhibitor aimed at treating ...

BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class 1 targeted and immune-mediated ...

to evaluate TPST-1495, the company’s novel dual receptor inhibitor of prostaglandin, PGE2, signaling, in a Phase 2 clinical trial for the treatment of patients with Familial Adenomatous ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Called “L’Exposition internationale des arts décoratifs,” it ran from April to October 1925, attracted 16 million people, and was a celebration of Modernism and Art Deco design. It occupied ...

We Are Innovators. We Are Thinkers. We Are Creatives. We are one of the world’s leading art and design schools and we have been influencing, inspiring and innovating for over 175 years. We are guided ...

A pioneering course exploring the creative relationships between art and science, addressing the rapidly evolving landscape of interdisciplinary art practice. From October 2024, you can only apply for ...

Find out more in the Apply Now section. Whatever your art specialism, this online learning space allows you to question fine art practice in a digital context. This course is part of the Art programme ...